Projected impact ofCervarix®vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom

Effelterre, Thierry Van; Hogea, Cosmina; Taylor, Stephen

doi:10.4161/hv.28834

Cited by 3 publications

(1 citation statement)

References 35 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several mathematical models have estimated the potential population impact of HPV vaccination on the burden of cervical cancer [ 16 – 22 ]. In Italy, like in other countries in Europe, there are numerous published studies assessing the cost-effectiveness of HPV vaccines [ 9 , 19 , 23 – 28 ].…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy

Mennini

Bonanni

Bianic³

et al. 2017

Cost Eff Resour Alloc

View full text Add to dashboard Cite

BackgroundIn Italy HPV vaccination with the quadrivalent vaccine (Gardasil®) is offered actively and free of charge to girls aged 12 since 2007. A nine-valent vaccine (Gardasil 9®) received the European market authorization in 2015 to protect, with only 2 doses, against around 90% of all HPV positive cancers, over 80% of high-grade precancerous lesions and 90% of genital warts caused by HPV types 6/11.MethodsA dynamic transmission model simulating the natural history of HPV-infections was calibrated to the Italian setting and used to estimate costs and QALYs associated with vaccination strategies. The analyses compared two strategies with the nine-valent vaccine (cervical cancer screening and vaccination in girls only or vaccination in boys and girls) to four alternative strategies (cervical cancer screening and vaccination with quadrialent vaccine in girls only, in both boys and girls, with bivalent vaccine in girls and screening strategy only). The National Health Service perspective was considered.ConclusionThe switch to the nine-valent vaccine in Italy can further reduce the burden associated to cervical cancer and HPV-related diseases and is highly cost-effective.ResultsCompared to the current vaccination program with quadrivalent vaccine, the nine-valent vaccine in a programme including girls and boys shows further reductions of 17% in the incidence of cervical cancer, 35 and 14% in anal cancer for males and females, as well as over a million cases of genital warts avoided after 100 years. The new technology is associated with an ICER of 10,463€ per QALY gained in universal vaccination, decreasing to 4483€ when considering the vaccine switch for girls-only.Electronic supplementary materialThe online version of this article (doi:10.1186/s12962-017-0073-8) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy

Mennini

Bonanni

Bianic³

et al. 2017

Cost Eff Resour Alloc

View full text Add to dashboard Cite

show abstract

Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France

Majed¹,

Bresse²,

Mouaddin³

et al. 2021

Vaccine

View full text Add to dashboard Cite

Cancer Incidence Among Adolescents and Young Adults (15 to 29 Years) in Brazil

Balmant¹,

Reis²,

Oliveira³

et al. 2016

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

The spectrum of cancers commonly found in adolescents and young adults (AYAs) differs from those in children and adults; therefore, the childhood classification is not appropriate for this population. Here we used a newly proposed classification system to reclassify cases of AYAs from Brazilian population-based cancer registries (PBCRs) in 5 geographic regions of Brazil. We aimed to describe the cancer incidence rates within this age group according to PBCR. Using the world population, incidence rates per million were analyzed in each diagnostic subgroup according to sex and age at diagnosis (15 to 19 y, 20 to 24 y, and 25 to 29 y). The median incidence rate was 232.31 per million for females and 218.07 per million for males. Incidence increased with age, with the highest rate observed for 25- to 29-year-olds in both sexes. Carcinomas, lymphomas, and skin tumors were most frequent among AYAs. High incidence rates of cervix-uterus carcinoma were observed in most PBCRs. AYAs present epidemiological characteristics that differ from those of children, reinforcing the need for a new classification. This study describes, for the first time, the cancer incidence rate in AYAs in Brazil, and we believe that our findings represent the Brazilian profile.

show abstract

Projected impact ofCervarix^®vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom

Cited by 3 publications

References 35 publications

Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy

Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy

Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France

Cancer Incidence Among Adolescents and Young Adults (15 to 29 Years) in Brazil

Contact Info

Product

Resources

About